歌礼制药-B（01672）今日盘中大涨5.20%，引起投资者广泛关注。这一显著涨幅与公司最新发布的积极研发进展密切相关。
据悉，歌礼制药于3月31日宣布，其在美国开展的肥胖症新药ASC30的Ib期临床试验取得积极的期中结果。这项随机、双盲、安慰剂对照的研究针对体重指数在30-40 kg/m²之间的肥胖症患者，评估了含小分子ASC30的三种超长效皮下注射制剂。值得注意的是，ASC30被认为是首款也是唯一一款既可每日一次口服，又可每月一次或更低频率皮下注射的试验阶段小分子GLP-1R激动剂，用于治疗肥胖症。
这一研发进展显示了歌礼制药在肥胖症治疗领域的创新能力和潜在市场竞争力。肥胖症是一个巨大的全球健康问题，开发新的、更便利的治疗方案有望为公司带来可观的市场机会。投资者对这一积极消息反应热烈，推动公司股价在盘中显著上涨。未来，随着临床试验的进一步推进，市场将持续关注ASC30的开发进程及其潜在的商业化前景。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.